Showcasing the Development of DS-7300, a B7-H3-Directed DXd Antibody-Drug Conjugate

Time: 2:15 pm
day: Track C - Day 1 - PM

Details:

• Evaluating the pre-clinical profile and mechanism of action of DS-7300
• Sharing the clinical development status of DS-7300
• Discussing future developments of DS- 7300

Speakers: